The FDA’s Accelerated Approval (AA) program enables early approval of drugs that treat serious conditions by bypassing unmet regulatory conditions. Despite risks, the recent approval of Humacyte’s bioengineered blood vessels has sparked concerns over how medical devices are approved during this process.
View More FDA Approval of Bioengineered Blood Vessels Raises Concerns about Expedited Medical Reviews